Enliven Therapeutics, Inc. (ELVN)
NASDAQ:ELVN
Want to see ELVN full AI Analyst Report?
Top Page
Enliven Therapeutics
(NASDAQ:ELVN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$40.00
▼(-16.86% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by pre-revenue operations with sizable ongoing losses and persistent cash burn, alongside a valuation profile that cannot be supported by earnings (negative P/E). These risks are partially offset by a strong, low-debt balance sheet and a generally positive longer-term technical trend despite neutral/weak short-term momentum.
Positive Factors
Balance-sheet strength
A near-zero debt profile and materially larger equity base provide durable financial flexibility for multi-year R&D programs. This reduces refinancing pressure, allows the company to absorb trial costs, and supports strategic optionality such as partnerships or acquisition discussions.
Negative Factors
Pre-revenue operations
Being pre-revenue means long lead times to commercialization and dependence on clinical success to justify future cash flows. Continued lack of product revenue leaves the company exposed to binary trial outcomes and delayed monetization that can persist for years.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
A near-zero debt profile and materially larger equity base provide durable financial flexibility for multi-year R&D programs. This reduces refinancing pressure, allows the company to absorb trial costs, and supports strategic optionality such as partnerships or acquisition discussions.
Read all positive factors
Enliven Therapeutics (ELVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.55B
Dividend YieldN/A
Average Volume (3M)806.45K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue GrowthN/A
EPS Growth13.79%
CountryUS
Employees62
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.64
Shares Outstanding60,904,945
10 Day Avg. Volume670,317
30 Day Avg. Volume806,445
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-40.69K
Enterprise Value/Ebitda-22.06
Forecast
1Y Price Target
$57.14Price Target Upside18.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.02
Revenue Forecast (FY)$10.00K
Enliven Therapeutics Business Overview & Revenue Model
Company Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is...
How the Company Makes Money
As a clinical-stage biotechnology company, Enliven Therapeutics does not have recurring revenue from commercial drug sales unless and until a product is approved and launched. Its ability to generate revenue is primarily tied to strategic transact...
Enliven Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -60.00K | -263.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -110.65M | -119.39M | -104.24M | -83.23M | -38.58M | -24.65M |
| Net Income | -98.78M | -103.69M | -89.02M | -71.58M | -37.66M | -24.74M |
Balance Sheet | ||||||
| Total Assets | 464.85M | 476.17M | 325.76M | 271.87M | 83.30M | 113.33M |
| Cash, Cash Equivalents and Short-Term Investments | 452.40M | 462.62M | 313.44M | 253.15M | 75.54M | 110.02M |
| Total Debt | 302.00K | 399.00K | 0.00 | 335.00K | 323.00K | 159.00K |
| Total Liabilities | 11.49M | 16.68M | 15.91M | 25.96M | 160.12M | 6.47M |
| Stockholders Equity | 453.37M | 459.60M | 309.85M | 245.91M | -76.83M | 106.86M |
Cash Flow | ||||||
| Free Cash Flow | -65.60M | -70.46M | -73.24M | -61.42M | -32.69M | -19.32M |
| Operating Cash Flow | -65.47M | -70.30M | -73.19M | -61.27M | -32.08M | -19.13M |
| Investing Cash Flow | -132.74M | -173.84M | -36.00M | -148.41M | -612.00K | -191.00K |
| Financing Cash Flow | 228.69M | 218.87M | 133.16M | 234.29M | -1.80M | -1.02M |
Enliven Therapeutics Technical Analysis
Positive
48.11
Price Trends
39.71
Positive
32.73
Positive
26.34
Positive
Market Momentum
0.20
Positive
53.20
Neutral
43.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELVN, the sentiment is Positive. The current price of 48.11 is above the 20-day moving average (MA) of 41.83, above the 50-day MA of 39.71, and above the 200-day MA of 26.34, indicating a bullish trend. The MACD of 0.20 indicates Positive momentum. The RSI at 53.20 is Neutral, neither overbought nor oversold. The STOCH value of 43.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELVN.
Enliven Therapeutics Risk Analysis
Enliven Therapeutics disclosed 89 risk factors in its most recent earnings report. Enliven Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enliven Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.40B | -6.13 | -14.22% | ― | 242.66% | 15.53% | |
58 Neutral | $1.81B | 1.73 | 4.89% | ― | -2.20% | 77.51% | |
52 Neutral | $1.82B | -4.76 | -60.70% | ― | 23382.78% | 7.01% | |
52 Neutral | $1.71B | -3.95 | -57.27% | ― | 45.04% | 32.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $2.55B | -26.05 | -21.04% | ― | ― | 13.79% |
* Healthcare Sector Average
ELVN
Enliven Therapeutics
42.25
25.48
151.94%
SRPT
Sarepta Therapeutics
16.96
-21.83
-56.28%
VRDN
Viridian Therapeutics
17.69
4.02
29.41%
NTLA
Intellia Therapeutics
12.37
2.91
30.76%
ABCL
AbCellera Biologics
5.14
3.14
157.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.